MiMedx Group, Inc. (NASDAQ:MDXG – Free Report) – Equities research analysts at Northland Capmk boosted their FY2024 earnings estimates for MiMedx Group in a research report issued on Thursday, October 31st. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.28 for the year, up from their previous estimate of $0.23. The consensus estimate for MiMedx Group’s current full-year earnings is $0.28 per share. Northland Capmk also issued estimates for MiMedx Group’s Q4 2024 earnings at $0.07 EPS.
A number of other research analysts have also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price objective on shares of MiMedx Group in a report on Thursday, August 1st. StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Craig Hallum cut their price objective on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.00.
MiMedx Group Stock Performance
NASDAQ:MDXG opened at $7.29 on Monday. The company’s 50-day moving average is $6.07 and its two-hundred day moving average is $6.68. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of 13.25 and a beta of 1.94. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $9.27.
Institutional Investors Weigh In On MiMedx Group
A number of institutional investors have recently modified their holdings of MDXG. Isthmus Partners LLC boosted its holdings in MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after acquiring an additional 91,714 shares during the period. Headlands Technologies LLC acquired a new position in shares of MiMedx Group in the first quarter valued at approximately $27,000. Blue Trust Inc. purchased a new stake in MiMedx Group during the 3rd quarter worth approximately $30,000. Point72 Asset Management L.P. acquired a new stake in MiMedx Group during the 2nd quarter worth approximately $40,000. Finally, Entropy Technologies LP purchased a new position in MiMedx Group in the 3rd quarter valued at approximately $64,000. 79.15% of the stock is owned by institutional investors and hedge funds.
About MiMedx Group
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.
Recommended Stories
- Five stocks we like better than MiMedx Group
- 3 Tickers Leading a Meme Stock Revival
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Insider Buying Signals Upside for These 3 Stocks
- Why Are These Companies Considered Blue Chips?
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
